BioPorto Diagnostics have through dedicated research and product development been able to offer a strong range of antibodies and Immunoassays, which can be used for pharmaceutical as well as scientific research. We offer several antibodies with high specificity within medical specialties such as Obesity, Diabetes and Primary Immune Deficiency.
Our dedicated approach to identify and target biomarkers addressing unmet clinical needs in the management of acute conditions has enabled us to offer a novel biomarker for the diagnosis of acute kidney injury.
We have launched The NGAL Test, a market leading unique immunoassay solution for early risk assessment of acute kidney injury in several medical and surgical specialties.
The NGAL Test is not avaliable in the USA for in vitro diagnostic use.
The NGAL Test – first diagnostic acute kidney injury biomarker which can be measured in both human urine and plasma.The NGAL Test is a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) on automated clinical chemistry analyzers. NGAL measurements are useful in the diagnosis of acute kidney injury which may lead to acute renal failure.
The NGAL Test is not available in the USA for in vitro diagnostic use.BUY ONLINE
At BioPorto Diagnostics, we know the critical value of reliability and consistency in research as in medical care of patients. Immonuassays from BioPorto are developed with this in mind and our offering consist of unique solutions for diagnostic companies as well as Health Care Professionals.BUY ONLINE
On a continued basis, we offer new high specificity monoclonal antibodies for pharmaceutical research and for developing diagnostic immunoassays kits. We have unique antibodies in areas such as diabetes and obesity, allergy and immune deficiency.BUY ONLINE